首页/数据集/Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer

Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer

NIAID Data Ecosystem2026-03-06 收录

结直肠癌治疗

无进展生存期

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2618959 数据链接链接失效反馈

官方服务：

资源简介：

Interventions: XELOX+BV regimen (Capecitabine, Oxaliplatin, Bevacizumab) Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

应用场景：

创建时间：

2010-05-15

结直肠癌治疗

靶向药物疗效评估

Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been pre

NIAID Data Ecosystem50

A multicenter phase II study of FOLFIRI as first-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with homozygous for UGT1A1(FLIGHT1)

结直肠癌治疗

药物剂量优化

Interventions: On Day 1, patients treated with FOLFIRI therapy received a 2-hour intravenous infusion of CPT-11 (150 mg/m2) combined with 1-LV (200 mg/m2), followed by a rapid intravenous infusion of

NIAID Data Ecosystem30

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

结直肠癌治疗

肿瘤血管

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer ce

NIAID Data Ecosystem20

Supplementary Material for: Patient’s Skeletal Muscle Radiation Attenuation and Sarcopenic Obesity are Associated with Postoperative Morbidity after Neoadjuvant Chemoradiation and Resection for Rectal Cancer

医学研究

结直肠癌治疗

Background/Aims: To investigate the relation between skeletal muscle measurements (muscle mass, radiation attenuation, and sarcopenic obesity), postoperative morbidity, and survival afte

DataCite Commons2020-08-29 更新50

S1.

药物靶点识别

结直肠癌治疗

The targets of six groups of the main drug component β- Elemene γ- Elemene and δ- Elemene in Elemene Liposome , as well as colorectal adenoma (CA), colorectal cancer (CC) and innate immunity (II)

Figshare2022-04-09 更新20

Multicenter Phase II Study of XELOX with Bevacizumab in the Late Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer

资源简介：

相关数据集